Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 7/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | AKR1C4 | P17516 | 3/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.53 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7890737 | 0.88 | MAPT (0.69) | ALDH1A1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL30739671 | 0.88 | MAPT (0.69) | ALDH1A1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL14426490 | 0.80 | HDAC1 (0.70) | ALDH1A1MEN1KMT2AGFERMAPT | |
| SCHEMBL22887353 | 0.79 | CDC25B (0.58) | AKR1C4AKR1C3AKR1C2AKR1C1CA12 | |
| SCHEMBL7881117 | 0.79 | DEGS1 (0.63) | ALDH1A1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL11133928 | 0.79 | ESR1 (0.51) | ALDH1A1MEN1KMT2AGFERMAPT | |
| SCHEMBL7888080 | 0.78 | MAPT (0.72) | ALDH1A1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL15652630 | 0.78 | UNG (0.60) | ALDH1A1MEN1KMT2AGFERMAPT | |
| SCHEMBL12431978 | 0.78 | MEN1 (0.59) | ALDH1A1MEN1KMT2AGFERMAPT | |
| SCHEMBL4830911 | 0.77 | MAPT (0.49) | ALDH1A1MEN1KMT2AMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | UNIV INDIANA TRUSTEES (US) | 2022-05-12 | — | — | US | disclosed |
| US-20210009498-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | THE TRUSTEES OF INDIANA UNIVERSITY | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | ADM2, DDAH1, BHMT | ALDH1A1 336/4885MEN1 2027/4885KMT2A 1644/4885 |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | ADM2, DDAH1, BHMT | ALDH1A1 336/4885MEN1 2027/4885KMT2A 1644/4885 |
| US-20210009498-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | ADM2, DDAH1, BHMT | ALDH1A1 336/4885MEN1 2027/4885KMT2A 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.